Cipher Pharmaceuticals Inc (CPH.TO) experienced a slight decline this week amid recent announcements and ongoing market conditions.
Cipher Pharmaceuticals Inc has seen its stock price decrease by 1.94% today and 2.98% over the past week, closing at C$14.19. The company recently reported its second-quarter results, which included significant developments in its product sales and partnerships.
Advertisement
Cipher Pharmaceuticals Inc
CPH.TO
CPH.TO
Cipher Pharmaceuticals Inc
WealthAwesomeMarket cap
$354.54M
P/E
9.0x
52W high
$20.56
52W low
$12.48
1W change
-2.98%
Beta
0.46
Analyst Price Targets
Based on analyst covering CPH
Wall Street analysts forecast CPH stock price to rise 45.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$19.95
+45.8% Upside
Current Price
C$13.68
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CPH's historical volatility
30-Day Vol
73.6%
Annualized
90-Day Vol
50.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$11.44
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$12.89 | C$10.00 – C$16.61 |
| 60 trading days | C$12.14 | C$8.48 – C$17.39 |
| 90 trading days | C$11.44 | C$7.37 – C$17.76 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should note the company's positive sales trajectory for Epuris® and its strategic partnerships, despite recent stock price declines. The debt-free balance sheet and strong profit margins may provide a buffer against market fluctuations.
Cipher Pharmaceuticals Reports 14% Increase in Epuris® Sales.
Despite a decrease in total revenue, the growth in Epuris® sales suggests solid demand for its products, which could drive future performance.
Bull case
Cipher's recent announcement of a 14% increase in Epuris® sales and a debt-free balance sheet indicate strong operational stability and growth potential. This growth in sales shows that there is a solid demand for Epuris®, which could bode well for the company moving forward.
Bear case
On the downside, the stock has dropped 18.72% in the past month, and recent revenue figures show some pressure on total revenue, which may concern investors. This decline raises questions about the company’s ability to maintain its growth trajectory amid current market challenges.
Recent Price Action
This week, Cipher Pharmaceuticals Inc saw its stock price decline by 2.98%, closing at C$14.19. Today's trading resulted in a decrease of 1.94%. The stock has struggled over the past month, dropping 18.72%, reflecting broader market pressures and specific challenges within the company.
Company News and Catalysts
Advertisement
Cipher Pharmaceuticals recently announced its second-quarter results for 2026, highlighting a 14% year-over-year increase in Epuris® sales, which reached C$4.1 million. However, total revenue fell by 10% to C$12.1 million, and net income decreased by 32% to C$4.0 million. Additionally, the company executed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance to enhance patient access to Epuris® across Canada. The launch of a stocking program for Natroba™ at Walmart is also a significant development, aimed at improving product availability in the U.S. market.
Technical Picture
Cipher Pharmaceuticals' stock is currently trading below both its 50-day moving average of C$16.12 and its 200-day moving average of C$15.97, indicating a bearish trend. The stock's 52-week range is C$12.48 to C$20.56, with the current price at approximately 21% of that range. With a beta of 0.46, the stock is less volatile compared to the broader market. The latest trading volume of 43,936 shares is below the 20-day average volume of 68,888 shares, suggesting lower investor interest in the recent sessions.
Insider Activity
Currently, there are no reported insider activities for Cipher Pharmaceuticals that would provide additional context for investors.
Price Action Summary
Cipher Pharmaceuticals Inc closed at C$14.19, reflecting a 1D decline of 1.94%. Despite the recent challenges, the company’s growth in Epuris® sales and strategic initiatives may provide a foundation for recovery.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
